AHCY

Across TCGA pan-cancer cohorts, AHCY mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AHCY data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AHCY mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated AHCY expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where AHCY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.841	0.555	.005	17	view →
CCRCC	DFS	Median	II,III,IV	0.956	0.782	.018	12	view →
LUAD	OS	Tertile	All	0.987	0.599	.010	11	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
PDAC	DFS	Quartile	II,III,IV	0.512	0.283	.032	2	view →
GBM	OS	Quartile	All	0.973	0.786	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AHCY–LSCC (DFS)

Open the LSCC breakdown →